Not specifiedRegulatory Approvalregulatorymid-term

FDA Submission Overview for ANDA217477 by Hainan Poly Pharm

Importance6/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/29/2026, 6:31:55 PM

Assessment confidence: 57% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of ANDA217477 by Hainan Poly Pharm signifies a new entrant into the market, which could disrupt existing competitive dynamics. Portfolio teams must evaluate the implications for their products and strategies in response to this regulatory development. Regulatory context from FDA (FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026) supports the near-term read. Assessment grounded in 20 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this submission on existing products and market dynamics. The strongest clinical anchor is A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025) (ClinicalTrials.gov), sponsor/company relevance (merck). In Not specified, 3 regulatory and 4 competitive items passed relevance filtering for ANDA217477.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. The submission indicates Hainan Poly Pharm's entry into the market, potentially increasing competition in the relevant therapeutic area.

Regulatory Outlook

Regulatory risk is concentrated around FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026 (FDA). Moderate corpus alignment. Relevant agencies in corpus: FDA, MHRA. The standard review priority indicates a typical timeline for approval, which could lead to new market entries and necessitate adjustments in compliance and labeling for competitors.

Key Risks

Elevated medium regulatory exposure for ANDA217477 could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Increased competition from Hainan Poly Pharm may affect market share and pricing strategies for existing products in the therapeutic area, potentially impacting revenue.
Upside for ANDA217477 may improve if Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease (ClinicalTrials.gov) delivers favorable follow-through.
Upside for ANDA217477 may improve if The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this submission on existing products and market dynamics.

What Would Change This Assessment

This becomes more urgent if Monitor the review progress and any subsequent approvals or market entries related to ANDA217477.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Register to make submissions to the MHRA
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Urinary Vitamin C Loss in Diabetic Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Characterization of Phenotypic and Genotypic Regressors for Imaging
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Zydus' Edaravone ANDA218349
Humanexa Signalsmedium relevance
Moderate corpus alignment

Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An integrated approach combining transcriptomics, network pharmacology, and experimental validation are used to investigate the mechanism of Lonicerae Japonicae Flos and Forsythiae Fructus extracts ag
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Ethnopharmacological potential and mechanistic study of Platycodon grandiflorum stems and leaves and Lonicera japonica stems and leaves against acute lung injury.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

ANDA217477
existing market competitors

Commercial impact

medium

Increased competition from Hainan Poly Pharm may affect market share and pricing strategies for existing products in the therapeutic area, potentially impacting revenue.

Regulatory impact

medium

The standard review priority indicates a typical timeline for approval, which could lead to new market entries and necessitate adjustments in compliance and labeling for competitors.

What to watch

Monitor the review progress and any subsequent approvals or market entries related to ANDA217477.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.